Mizuho Raises UiPath (NYSE:PATH) Price Target to $25.00

UiPath (NYSE:PATH) had its price target hoisted by Mizuho from $22.00 to $25.00 in a research note published on Thursday, Benzinga reports. Mizuho currently has a neutral rating on the healthcare company’s stock.

PATH has been the topic of several other reports. Barclays raised their target price on UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a research report on Friday. JPMorgan Chase & Co. raised UiPath from a neutral rating to an overweight rating and raised their target price for the stock from $22.00 to $28.00 in a research report on Thursday. Evercore ISI lifted their price objective on UiPath from $24.00 to $27.00 and gave the company an in-line rating in a research report on Thursday. William Blair assumed coverage on UiPath in a research report on Tuesday, January 2nd. They set an outperform rating on the stock. Finally, TD Cowen lifted their price objective on UiPath from $25.00 to $28.00 and gave the company an outperform rating in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, UiPath currently has an average rating of Hold and an average price target of $27.13.

UiPath Stock Up 1.4 %

NYSE:PATH traded up $0.32 on Thursday, hitting $23.07. The stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The stock has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The business’s 50-day simple moving average is $23.52 and its two-hundred day simple moving average is $20.70. UiPath has a 52-week low of $12.38 and a 52-week high of $27.87.

Insider Activity at UiPath

In related news, Director Rich Wong sold 200,000 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Ashim Gupta sold 70,000 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now owns 788,148 shares in the company, valued at approximately $18,143,166.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rich Wong sold 200,000 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 411,000 shares of company stock worth $9,418,670. Company insiders own 31.03% of the company’s stock.

Institutional Trading of UiPath

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in UiPath by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company’s stock worth $946,028,000 after purchasing an additional 334,085 shares during the period. BlackRock Inc. increased its stake in UiPath by 32.1% in the second quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock worth $387,354,000 after purchasing an additional 5,681,577 shares during the period. FMR LLC increased its stake in UiPath by 2.9% in the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after purchasing an additional 463,032 shares during the period. Goldman Sachs Group Inc. increased its stake in UiPath by 37.4% in the second quarter. Goldman Sachs Group Inc. now owns 11,662,087 shares of the healthcare company’s stock worth $193,241,000 after purchasing an additional 3,172,300 shares during the period. Finally, Altimeter Capital Management LP increased its stake in UiPath by 175.4% in the first quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock worth $71,579,000 after purchasing an additional 5,270,194 shares during the period. Hedge funds and other institutional investors own 59.04% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.